an integral membrane glycoprotein, is synthesized and processed by the rough ER and Golgi apparatus, and mature LDL-R appears on the cell surface. LDL binds to LDL-R and is internalized via coated vesicles, and LDL and LDL-R are sorted in endosomes.
tors synthesized, but transported slowly from the ER to the Golgi; class 3, receptors are processed and reach the cell surface, but fail to bind LDL normally; and class 4, receptors reach the cell surface and bind LDL, but fail to cluster in coated pits. Biochemical-genetic analysis of the LDL-R of fibroblasts derived from FH patients is limited because of the following reasons. 1. These cells do not grow well in vitro. 2. Application of somatic cell genetic techniques to primary cultured cells is often not possible. 3. The repertoire of naturally occurring mutations is limited. Therefore, as described below, development of somatic cell genetics with cultured mammalian cell mutants should be a very powerful system for overcoming the above limitations (see also ref. 3) .   II.  SOMATIC  CELL  GENETICS:  EXPERIMENTALLY  INDUCED  MUTA-TIONS IN THE LDL-R. 1. Single step selection of LDL-R mutants by Krieger. Krieger and his colleagues (3, 4, 5) have developed two methods for selection of LDL-R mutations in Chinese hamster ovary (CHO) cells. The first method is to (6) . They show poor receptor-mediated endocytosis of LDL, resulting in increased production of mevalonic acid, an intracellular competitor of compactin. Our resistant cell lines have a primary defect in their responses to LDL (6) . The biochemical properties of the compactin-resistant mutants isolated in these three laboratories appear to have depended on the cell lines and the selection procedures employed. Our mutants were selected for resistance to exposure to a single dose of compactin for a short time in the presence of lipoproteins. By using anti-LDL-R antibody, the structure and processing of the receptors were compared between compactin-resistant mutants (MF-1 and MF-2) and their parental V79 cells (7) . V79 cells produce the expected precursor form of 120,000 daltons, which can be labeled with [35S]methionine within a short time, and the mature form of 160,000 daltons. The precursor form is almost completely converted into a mature form after a 30-min chase. The molecular size of the precursor produced in MF-1 and MF-2 cells is similar to that in their parental V79 cells, whereas the mature form in each of the two compactin-resistant mutants is approximately 5,000 daltons smaller. LDL-R mRNA sizes are similar in MF-2 and V79 cells. Treatment of V79 and MF-2 cells with tunicamycin, a specific inhibitor of the addition of N-linked sugar chains to glycoproteins, does not diminish the difference in the molecular sizes of the mature forms in the two cell lines. Further study revealed no difference in the molecular sizes of the precursor forms between MF-2 and V79 LDL-R after treatment with O-glycanase, which removes desialyated O-linked sugar chains from glycoproteins (10) . These data suggest that our compactin-resistant mutants have LDL-R with altered O-linked sugar chain. We have also isolated monensin-resistant mutants from the CHO cell line. Monensin, an Na+ /K+ ionophoric antibiotic, inhibits intracellular membrane traffic such as protein secretion, pinocytosis, penetration of enveloped viruses, processing and maturation of glycoproteins. Most of these effects are probably related to the ability of monensin to increase the pH of endosomes, the acidic compartments of the Golgi apparatus and also lysosomes. Acquisition of monensin-resistant mutation is expected to alter membrane transport systems. In fact, a monensin-resistant mutant, Monr-31, shows altered pleiotropic responses to lectins, insulin, LDL, and vesicular stomatitis viruses. Yoshimura in our laboratory has found that the LDL-R number is similar in both CHO and Monr-31, but the binding affinity is reduced in the mutant (8, 9) . The precursor and degradation forms of the LDL-R produced in the mutant cells are similar in size to those in CHO cells, but the apparent molecular size of the mature receptor is reduced by about 5,000 daltons in Monr-31. Tests of the effects of tunicamycin, O-glycanase, and sialidase on the molecular size of the mature receptors indicate that the reduced size of LDL-R of Monr-31 is due to the O -glycosylation . The molecular sizes and the binding activity of human LDL-R were compared by transfecting CHO and Monr-31 with normal human LDL-R cDNA (pLDL-R-2). The human LDL-R produced in the transfected clones of Monr-31 was also smaller and lower in binding capacity than that produced in the transfected clone of CHO. The structural and functional alteration of the LDL-R of Monr-31 is not caused by a mutation in the structural LDL-R gene, but by altered maturation and M. Ono 
